Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension.

MLA

Grünig, Ekkehard, et al. “Oral Treprostinil Is Associated with Improved Survival in FREEDOM-EV and Its Open-Label Extension.” Advances in Therapy, vol. 41, no. 2, Feb. 2024, pp. 618–37. EBSCOhost, https://doi.org/10.1007/s12325-023-02711-x.

APA

Grünig, E., Rahaghi, F., Elwing, J., Vizza, C. D., Pepke-Zaba, J., Shen, J., Yao, H., Hage, A., Rosenkranz, S., Vonk, M., Balasubramanian, V., Yuanhua, Y., Yu, Z., Lordan, J., Cadaret, L., Grover, R., Ousmanou, A., Seaman, S., Deng, C., … White, R. J. (2024). Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension. Advances in Therapy, 41(2), 618–637. https://doi.org/10.1007/s12325-023-02711-x

Chicago

Grünig, Ekkehard, Franck Rahaghi, Jean Elwing, Carmine Dario Vizza, Joanna Pepke-Zaba, Jieyan Shen, Hua Yao, et al. 2024. “Oral Treprostinil Is Associated with Improved Survival in FREEDOM-EV and Its Open-Label Extension.” Advances in Therapy 41 (2): 618–37. doi:10.1007/s12325-023-02711-x.